About
Inductive Bio, founded in 2022 in San Francisco, uses AI to simulate protein-molecule interactions for drug discovery.
Technology & BusinessWhat · How · Which stage
Research AreasLife SciencesMedicine & PharmaMediumEvidence
通过模拟蛋白质与分子相互作用的方式，利用AI进行新药研发
Source：Official site · Updated 2026-09-10 · View source
Full tier & rationale — an SVTR Intelligence benefit
Capital graph
Funding history
- 2025-05Series A$25M
Investors · S32, Obvious Ventures, Andreessen Horowitz, Amino Collective, Lux Capital, Character VCSource · SVTR Weekly #104
- 2023-12Seed$4M
Investors · Character VC, Lux Capital, AlleyCorp, Bessemer Venture Partners, Andreessen HorowitzSource · SVTR Weekly #032
Comparable companies· by market
This company
BusinessLatest roundTotal raisedDate- Inductive Bio
AI drug discovery by simulating interactions between proteins and molecules
Series A · $29M · 2025-05
$29M
United States
BusinessLatest roundTotal raisedDate- PsiThera
Oral small-molecule drugs for immune and inflammatory diseases, using AI to model protein "kinetics" (QUAISAR™ platform)
Series A · $48M · 2025-12
$48M - Unnatural Products
Combines AI and chemistry to create new drugs, particularly synthetic drugs mimicking natural macrocycles
Undisclosed · $32M · 2023-12
$32M - Parallel Bio
AI and human immune tissue "organ-on-chip" models to predict drug efficacy
Series A · $21M · 2025-06
$21M
China
BusinessLatest roundTotal raisedDate- Levinthal Biotech
AI protein design services, with the proprietary all-atom protein design platform Pallatom
Series A · $14M · 2025-12
$14M - Drug Farm
Drug developer using genetics and AI to discover first-in-class targets
Series D+ · $55M · 2026-07
$55M - MindRank
Designs and develops novel small-molecule drugs using its in-house AI drug discovery platform MAP
Series B · $52M · 2026-07
$52M
Europe
BusinessLatest roundTotal raisedDate- Relation Therapeutics
Multi-omics plus active graph machine learning to discover and validate novel drug targets, partnered with GSK (fibrosis and osteoarthritis)
Undisclosed · $61M · 2025-12
$61M - Healx
AI to discover and develop treatments for rare diseases
Undisclosed · $47M · 2024-08
$47M - Turbine
Uses AI to simulate biological experiments, accelerating drug discovery and translational research
Series B · $25M · 2026-03
$25M
Other / unspecified
BusinessLatest roundTotal raisedDate- 深度细胞
Combines AI with multiscale molecular physics to build a "virtual cell world model" for disease mechanism discovery and drug design
Seed · $14M · 2026-08
$14M - Galux
AI plus physics-based protein/antibody design platform (GaluxDesign) for drug discovery
Series B · $58M · 2026-02
$58M - Mana.bio
Uses AI to design lipid nanoparticles for delivering mRNA to specific parts of the body
Seed · $20M · 2023-10
$20M
Confirmed rounds only. Matched on subsector, sector, stage and funding scale — each verifiable on the company profiles.
Investors that may fit
General Catalyst
40 Life Sciences deals in the last 24 months · 26 at a nearby stage · 36 in Silicon Valley
Request intro →Y Combinator
38 Life Sciences deals in the last 24 months · 33 at a nearby stage · 31 in Silicon Valley
Request intro →Khosla Ventures
21 Life Sciences deals in the last 24 months · 10 at a nearby stage · 20 in Silicon Valley
Request intro →Thrive Capital
18 Life Sciences deals in the last 24 months · 6 at a nearby stage · 15 in Silicon Valley
Request intro →Lightspeed
17 Life Sciences deals in the last 24 months · 11 at a nearby stage · 15 in Silicon Valley
Request intro →8VC
14 Life Sciences deals in the last 24 months · 9 at a nearby stage · 14 in Silicon Valley
Request intro →Ranked by each firm’s deals in this sector over the last 24 months, weighted by nearby stage and shared geography. Indicative only — no rating judgment.